Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of LuoBiTong tablet for active rheumatoid arthritis
ChiCTR2200060921Phase 3Not yet recruiting
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of luobitong in rheumatoid arthritis (RA) (2 arms), sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Proportion of subjects achieving ACR20. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
luobitong
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2200060921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060921.